{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:25:15Z","timestamp":1788585915002,"version":"build-2803163510"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":461,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n \n Infection with\n Mycobacterium ulcerans<\/jats:italic>\n (MU) causes extensive destruction of tissues with the formation of large ulcers on exposed parts of the body. Healing leads to extensive scarring and other complications which may impair function.\n <\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n To document the complications of MU disease and the reconstructive surgery performed to correct them.<\/jats:p>\n <\/jats:sec>\n \n Study design:<\/jats:title>\n Prospective from January 2010 to December 2012.<\/jats:p>\n <\/jats:sec>\n \n Setting:<\/jats:title>\n Ahafo Ano, Amansie West, Asunafo, and Upper Denkyira districts of Ghana.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients with unhealed lesions after completing 8 weeks of rifampicin and streptomycin treatment, and patients with complications of MU disease were selected and prepared for surgical treatment.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n 61 patients were treated successfully with rifampicin and streptomycin without complications. 65 patients presented with complications; they comprised 34 males and 31 females. Their ages ranged from 1 year 3 months to 80 years with mean age of 29.7 (S.D. 20.1).<\/jats:p>\n The types of lesions seen were ulcers (54), contractures (7), chronic osteomyelitis (one), subluxation of knee joint (one), salivary gland fistula (one) and Marjolin's ulcer (one). The lesions were distributed as follows: 69.2% on the lower, and 23.1% on the upper limbs, 6.2% on the head and neck and 1.5% on the trunk. Wound excision with or without skin grafting was done in 84.6% of patients, surgery for contractures in10.8%, and sequestrectomy, exploration and ligation of fistula, groin dissection and above knee amputation in 4.6%.<\/jats:p>\n <\/jats:sec>\n \n Conclusion[\/TAG:2]:<\/jats:title>\n Whilst ulcers, the commonest MU lesions, are being controlled with antibiotics, rare complications of the disease are also emerging.<\/jats:p>\n <\/jats:sec>","DOI":"10.1016\/j.ijmyco.2013.08.003","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T11:45:42Z","timestamp":1379418342000},"page":"206-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Management of complications of Mycobacterium ulcerans disease"],"prefix":"10.4103","volume":"2","author":[{"given":"Emmanuel J.K.","family":"Adu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20260904","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.283.5403.854","article-title":"Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence","volume":"283","author":"George","year":"1999","journal-title":"Science"},{"key":"R2-4-20260904","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1073\/pnas.0305877101","article-title":"Giant plasmidencoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans","volume":"101","author":"Stinear","year":"2004","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"R3-4-20260904","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/infdis\/157.3.577","article-title":"Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans","volume":"157","author":"Pimsler","year":"1988","journal-title":"J. Infect. Dis"},{"key":"R7-4-20260904","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(09)61962-0","article-title":"Antimicrobial treatment for early limited Mycobacterium ulcerans infection: a randomized control trial","volume":"375","author":"Nienhuis","year":"2010","journal-title":"Lancet"},{"key":"R8-4-20260904","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4314\/gmj.v45i1.68914","article-title":"Surgical management of Buruli ulcer disease: a four year experience from four endemic districts in Ghana","volume":"45","author":"Adu","year":"2011","journal-title":"Ghana Med. J"},{"key":"R9-4-20260904","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3201\/eid0802.010119","article-title":"Buruli ulcer in Ghana: results of a National case search","volume":"8","author":"Amofah","year":"2002","journal-title":"Emerg. Infect. Dis"},{"key":"R10-4-20260904","first-page":"4029","article-title":"Promising clinical efficacy of streptomycin\u2013rifampicin combination for treatment of Buruli ulcer (Mycobacterium ulcerans) disease","volume":"5","author":"Charity","year":"2009","journal-title":"Antimicrob. Agents Chemother"},{"key":"R11-4-20260904","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/AAC.49.8.3182-3186.2005","article-title":"Efficacy of the combination rifampicin\u2013streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans","volume":"49","author":"Etuaful","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"R13-4-20260904","first-page":"25","article-title":"Squamous cell carcinoma secondary to Buruli ulcer: a clinical case report in a young girl","volume":"55","author":"Kassi","year":"2010","journal-title":"Bacteriol. Virusol. Parazitol. Epidemiol"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553113000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553113000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01929415-201302040-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:01:04Z","timestamp":1788537664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01929415-201302040-00004"}},"subtitle":["A three-year review"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijmyco.2013.08.003","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}